{
     "PMID": "18757185",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20090420",
     "LR": "20131121",
     "IS": "1873-7862 (Electronic) 0924-977X (Linking)",
     "VI": "19",
     "IP": "1",
     "DP": "2009 Jan",
     "TI": "BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.",
     "PG": "1-13",
     "LID": "10.1016/j.euroneuro.2008.07.002 [doi]",
     "AB": "UNLABELLED: Reduced brain gamma-amino-butyric acid (GABA) participates in the pathogenesis of schizophrenia. GABA scarcely penetrates the brain. We evaluated the pharmacological properties of BL-1020, a novel GABA ester of perphenazine. Oral BL-1020 or perphenazine were assessed in acute and subchronic schizophrenia rat models. Catalepsy, serum prolactin, receptor binding profile and cortical (PFC), hippocampal (Hip) and dopamine (DA) levels were determined. Radioactive [14C] labeled BL-1020 was used for pharmacokinetics (PK). Acute and subchronic treatment with BL-1020 antagonized amphetamine-induced hyperactivity, with significantly lower catalepsy and sedation compared to equimolar perphenazine. At the same time, BL-1020 increased DA release in the PFC and Hip. BL-1020 and perphenazine stimulated prolactin secretion equally. BL-1020 displayed strong DA and serotonin (5HT) receptor inhibition (D(2L)K(iz)=0.066 nM, D(2S)K(i)=0.062 nM, 5-HT(2A)K(i)=0.21 nM). PK data revealed that BL-1020 penetrated the brain. CONCLUSIONS: The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation.",
     "FAU": [
          "Geffen, Yona",
          "Nudelman, Abraham",
          "Gil-Ad, Irit",
          "Rephaeli, Ada",
          "Huang, Mei",
          "Savitsky, Kinneret",
          "Klapper, Leah",
          "Winkler, Ilan",
          "Meltzer, Herbert Y",
          "Weizman, Abraham"
     ],
     "AU": [
          "Geffen Y",
          "Nudelman A",
          "Gil-Ad I",
          "Rephaeli A",
          "Huang M",
          "Savitsky K",
          "Klapper L",
          "Winkler I",
          "Meltzer HY",
          "Weizman A"
     ],
     "AD": "BioLineRx Ltd., 19 Hartum Street, Jerusalem, Israel.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20080830",
     "PL": "Netherlands",
     "TA": "Eur Neuropsychopharmacol",
     "JT": "European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology",
     "JID": "9111390",
     "RN": [
          "0 (Antipsychotic Agents)",
          "0 (Central Nervous System Stimulants)",
          "0 (perphenazine GABA ester)",
          "56-12-2 (gamma-Aminobutyric Acid)",
          "9002-62-4 (Prolactin)",
          "CK833KGX7E (Amphetamine)",
          "FTA7XXY4EZ (Perphenazine)",
          "N9YNS0M02X (Acetylcholine)",
          "VTD58H1Z2X (Dopamine)"
     ],
     "SB": "IM",
     "MH": [
          "Acetylcholine/metabolism",
          "Amphetamine/antagonists & inhibitors/toxicity",
          "Animals",
          "Antipsychotic Agents/*adverse effects/pharmacokinetics/*pharmacology",
          "Biological Availability",
          "Brain/metabolism",
          "Catalepsy/*chemically induced",
          "Central Nervous System Stimulants/antagonists & inhibitors/toxicity",
          "Dopamine/metabolism",
          "Hippocampus/drug effects/metabolism",
          "Male",
          "Microdialysis",
          "Motor Activity/drug effects",
          "Perphenazine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology",
          "Prefrontal Cortex/drug effects/metabolism",
          "Prolactin/metabolism",
          "Radioligand Assay",
          "Rats",
          "Rats, Sprague-Dawley",
          "Rats, Wistar",
          "Schizophrenia/*drug therapy",
          "Tissue Distribution",
          "gamma-Aminobutyric Acid/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology/*physiology"
     ],
     "EDAT": "2008/09/02 09:00",
     "MHDA": "2009/04/21 09:00",
     "CRDT": [
          "2008/09/02 09:00"
     ],
     "PHST": [
          "2008/03/19 00:00 [received]",
          "2008/06/28 00:00 [revised]",
          "2008/07/08 00:00 [accepted]",
          "2008/09/02 09:00 [pubmed]",
          "2009/04/21 09:00 [medline]",
          "2008/09/02 09:00 [entrez]"
     ],
     "AID": [
          "S0924-977X(08)00173-9 [pii]",
          "10.1016/j.euroneuro.2008.07.002 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Eur Neuropsychopharmacol. 2009 Jan;19(1):1-13. doi: 10.1016/j.euroneuro.2008.07.002. Epub 2008 Aug 30.",
     "term": "hippocampus"
}